Burning Rock Biotech - BNR EV/EBITDA Multiple

Burning Rock Biotech (BNR) utilizes external cloud storage for genetics, maintaining a moderate dependence on IT providers. The business faces stringent regulatory pressure and competition from state entities in the PRC. Market price action on GURU.Markets shows that the EV/EBITDA multiple is 0.00. The platform has currently reached a peak of scientific activity, accelerating the launch of liquid biopsy systems for early diagnosis.

BNR Burning Rock Biotech Ltd: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization in the range 11/23/2025 - 11/12/2026

Analytical breakdowns for Burning Rock Biotech

- market price and analyst price targets:

Price Chart Burning Rock Biotech Ltd.|BNR - Broker Consensus Forecast

- issuer market value details:

Market Capitalization Burning Rock Biotech Ltd|BNR - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Burning Rock Biotech|BNR - Company Book Value|Market Cap to Net Assets Ratio brbiotech.com|BNR - Company Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

BNR - Net Profit|Expected Profit Burning Rock Biotech|BNR - Company Value to Net Income|Future Price to Earnings Burning Rock Biotech|BNR - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Burning Rock Biotech Ltd|BNR - Operating income before deduction of amortization|Earnings per share for the last twelve months Burning Rock Biotech|BNR - Earnings per share for the last 12 months|Quarterly EPS earnings growth brbiotech.com|BNR - Net earnings per share change in current year|Expected earnings per share growth for next year Burning Rock Biotech

Comprehensive company analysis:BNR (Burning Rock Biotech Ltd.)

High debt leverage leaves the business vulnerable to shocks, yet Burning Rock Biotech (BNR) leadership in Chinese molecular cancer diagnostics creates a significant fundamental margin of safety. By analyzing the EV/EBITDA multiple in conjunction with the capital structure, an investor assesses the total enterprise value relative to operating cash flow before depreciation and taxes, which allows for the determination of the actual market revaluation of the company's assets.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Caris CAI|GH: Enterprise Value to Operating Income Before Depreciation|Veracyte, Inc. - EV/EBITDA Multiple|CELC - EV/EBITDA Multiple|GRAIL (GRAL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MYGN (Myriad Genetics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CSTL|Company Value to EBITDA VolitionRx Ltd VNRX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biodesix, Inc. (BDSX)|Total Company Value to Operating Income Before Depreciation Ratio precipiodx.com|EV/EBITDA Multiple CHEK (Check-Cap)|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization